Dipeptidyl peptidase IV (DPPIV) inhibition is believed to exert its antidiabetic effects by enhancing the production of incretins such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1), and GLP-1 receptors have also been found in extra-pancreatic tissues and incretin-based agents have been shown to have possible pleiotropic actions beyond glucose control. [1] [2] [3] [4] [5] [6] Many experimental and clinical trials have concluded that DPPIV inhibition decreases albuminuria in DN and can potentially delay the onset and progression of DN, in addition to improving kidney function in glycemic controls. [7] [8] [9] [10] [11] [12] [13] [14] Numerous studies have provided evidence that podocyte dysfunction, such as podocyte loss, has a central role in the development and progression of DN. 15, 16 For example, the decreased nephrin expression observed in DN has been associated with increased albuminuria, and recent reports have also demonstrated that DPPIV expression is upregulated in the glomeruli of patients with DN. 7, [17] [18] [19] Moreover, DPPIV inhibition has been shown to delay DN progression by attenuating podocyte injury via a glucose-independent mechanism. 7 Furthermore, DPPIV inhibition has been shown to improve proteinuria, podocyte function in an animal model of obesity-related glomerulopathy. 20 Taken together, these findings indicate that DPPIV inhibition may affect podocyte function in DN.
However, few reports have evaluated the role of DPPIV on renal injury, specifically on podocyte injury, in a mouse model of type 2 diabetes. Thus, here we investigated the effects of DA-1229, a novel DPPIV inhibitor, on DN in db/db mice. In addition, we also utilized a mouse model of chronic progressive kidney disease characterized by podocyte injury, adriamycin nephropathy, to examine the effect of DPPIV inhibition on the progression of renal disease. In addition, to elucidate the molecular mechanism by which DPPIV acts, we performed in vitro experiments using cultured podocytes to evaluate the effects of high glucose and angiotensin II on DPPIV activity and nephrin levels.
MATERIALS AND METHODS Animal Studies
Animal studies were conducted in two different mouse models of disease, type 2 diabetes and adriamycin nephropathy. For the type 2 diabetes model, six-week-old male diabetic db/db mice (C57BLKS/J-lepr db /lepr db ) and male nondiabetic db/m mice (C57BLKS/J-lepr db /+) were purchased from The Jackson Laboratory (Sacramento, CA, USA). DA-1229 (evogliptin) tartrate, a DPPIV inhibitor, was obtained from Dong-A ST Research Institute (Yongin, Republic of Korea). Mice were divided into three experimental groups (n = 8 per group): nondiabetic db/m mice as nondiabetic controls, untreated db/db mice and drug-treated db/db mice. Mice were fed with either normal chow or 0.3% DA-1229-chow admixture (mean administered dose of 297.2 ± 0.10 mg/kg/day) for 12 weeks from 8 weeks of age. For the adriamycin model, 10-week-old male BALB/c mice were administered a single intravenous injection of adriamycin (doxorubicin hydrochloride; Sigma, St Louis, MO, USA) at 13 mg/kg. These conditions were chosen based on preliminary experiments showing that a single tail vein injection of this dose induced significant proteinuria and progressive glomerulosclerosis by 3 weeks after injection. For the adriamycin model, preventive and therapeutic protocols were performed (n = 7 per group). To analyze the preventive effects of DA-1229 in adriamycin model, DA-1229 was administered in mixed chow at a dose of 300 mg/kg/day for 3 weeks beginning with the adriamycin injection. Mice were then killed 3 weeks after the adriamycin injection. For the therapeutic protocol, DA-1229 treatment was initiated 3 weeks after adriamycin injection and the treatment was continued for 2 weeks. Mice were then killed at 5 weeks post-adriamycin injection. All mice were provided with a standard diet and water and were maintained in a temperature-controlled (23 ± 2°C) and humidity-controlled (55 ± 5%) room with a 12-h light/12-h dark cycle. Daily food intake was monitored at regular intervals to confirm drug administration. During experiments, food intake, water intake, urine volume, body weight, fasting blood glucose concentration and HbA1c levels were measured monthly. Blood glucose levels were measured using the glucose oxidase-based method and plasma creatinine levels were determined by HPLC. Plasma insulin and adiponectin levels were measured using an ELISA kit (Linco Research, St Charles, MO, USA). The homeostasis model assessment index (HOMA-IR) was calculated by the following equation: fasting glucose (mmol/l) x fasting insulin (mU/l)/ 22.5. Plasma triglyceride and cholesterol analyses were performed using a GPO-Trinder kit (Sigma-Aldrich, St Louis, MO, USA). Plasma lipoprotein profiles were measured using a fast protein HPLC system. To determine urinary albumin excretion, individual mice were caged once each month in a metabolic cage, and urine was collected for 24 h. Urinary albumin concentrations were determined by a competitive ELISA kit (ALPCO, Westlake, OH, USA). Urinary nephrin concentrations were also determined by an ELISA kit (Exocell, Philadelphia, PA, USA) and corrected according to urine creatinine concentrations. Plasma active GLP-1 levels were determined by an ELISA kit (Millipore, St Charles, MO, USA). Plasma MCP-1 concentrations were assessed by an ELISA kit (Abcam Plc, Cambridge, MA, USA). Plasma and urinary levels of 8-isoprostane were measured using an ELISA kit (Cayman Chemical, Ann Arbor, MI, USA). At the end of the study period, systolic blood pressure was measured using tail-cuff plethysmography with an LE 5001-Pressure Meter (Letica SA, Barcelona, Spain). Mice were killed under anesthesia through i.p. injections of sodium pentobarbital (50 mg/kg). All ELISA analyses were performed in triplicate, and the results were averaged. All experiments were conducted in accordance with NIH guidelines and with the approval of the Korea University Institutional Animal Care and Use Committee.
DPPIV Activity Assay DPPIV activity was measured in plasma, cells and tissues as previously described. 21 Briefly, 0-40 μM of AMC (7-amino-4-methylcoumarin) standard was loaded into each well and read fluorometrically at Em/Ex = 360/465 nm, generating a linear standard curve. Next, 50 μl of plasma sample was added to each of the 96-wells, followed by the addition of 50 μl substrate solution (final concentrations 0.1 M HEPES, 50 μM Gly-Pro-AMC and 50 μg/ml BSA) per well. Free AMC, which was released by DPPIV activity, was quantitated by fluorometric measurements every 25 s for 300 s using a Spectramax GEMINI XPS microplate reader (Molecular Devices, Sunnyvale, CA, USA; Em/Ex = 360/465 nm, target temperature = 25
º C). To analyze DPPIV activity in renal tissue and cells, frozen tissue (10 mg) or cells (2 × 10 6 ) were homogenized in cold assay buffer (25 mM Tris-HCl, 140 mM NaCl, 10 mM KCl, pH 7.5, 0.1% BSA) and spun by centrifugation at 20 000 g for 20 min at 4 º C. DPPIV activity in the lysates was measured as described above. DPPIV activity in each tissue sample was expressed as the amount of cleaved AMC per minute per gram of tissue (μM/min/g tissue).
Histological and Immunohistochemical Analysis Kidney and hepatic tissue samples were fixed in 4% paraformaldehyde and embedded in paraffin. Samples were cut into 4-μm thick slices and stained with periodic acid-Schiff or hematoxylin and eosin. For immunohistochemical staining, sections were microwaved for 10-20 min to retrieve antigens for TGF-β1, nephrin, α-SMA, WT-1 and F4/80 staining. Alternatively, sections were transferred to Biogenex Retrievit buffer (pH 8.0) (InnoGenex, San Ramon, CA, USA) and microwaved for 10-20 min for antigen retrieval for plasminogen activator inhibitor (PAI)-1 staining, or treated with trypsin (Sigma) for 30 min at 37°C to detect type IV collagen. To block endogenous peroxidase activity, 3.0% H 2 O 2 in methanol was applied to the tissue sections for 20 min. Samples were then incubated at room temperature for 60 min in 3% BSA/3% normal goat serum (type IV collagen, α-SMA, WT-1 and F4/80), 30 min with 5% normal goat serum (nephrin), 15 min with 10% powerblock (PAI-1) or 30 min with 20% normal sheep serum (TGF-β1). Slides were incubated overnight at 4°C with rabbit polyclonal anti-TGF-β1 antibodies (1:200; Santa Cruz Biotechnology), rabbit polyclonal anti-WT-1 antibodies (1:400, Santa Cruz Biotechnology), mouse monoclonal anti-F4/80 antibodies (1:100; Serotec, Raleigh, NC, USA), rabbit polyclonal anti-type IV collagen antibodies (1:150; BioDesign International, Sarco, ME, USA), guinea pig polyclonal anti-nephrin antibodies (1:50; PROGEN Biotechnik GmbH, Heidelberg, Germany), rabbit polyclonal anti-PAI-1 antibodies (1:60; American Diagnostica, Stamford, CT, USA) or rabbit polyclonal anti-α-SMA antibodies (1:100; Santa Cruz Biotechnology). After overnight incubation, slides were incubated with secondary antibodies for 30 min. Immunoreactive areas were detected by incubation at room temperature with a mixture of 0.05% 3,3-diaminobenzidine containing 0.01% H 2 O 2 followed by counterstaining with Mayer's hematoxylin. Negative control sections were stained under identical conditions but with a buffer solution instead of the primary antibody. Glomerular mesangial expansion in diabetic mice was scored semiquantitatively as described previously, 22 and the degree of glomerulosclerosis in the adriamycin nephropathy model was scored according to the method described by Ma et al. 23 Macrophages infiltrating the interstitium were counted and expressed as the number of macrophages per high-power field. After α-SMA staining, the degree of tubulointerstitial fibrosis was assessed by a point-counting method as described previously. 24 To evaluate the immunohistochemical staining for type IV collagen, TGF-β1, PAI-1, WT-1 and F4/80, glomerular fields were graded semiquantitatively under a high-power field containing 50-60 glomeruli and an average score was calculated as described previously. 22 All histologic examinations were conducted by a trained pathologist in a blinded manner.
Analysis of Gene Expression by Real-Time Quantitative PCR Total RNA was extracted from renal cortical tissue samples and cells with Trizol reagent and further purified using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). Primers were designed from respective gene sequences using Primer 3 software and the secondary structures of the templates were examined and excluded using mfold software. The nucleotide sequences of all primers used in this study are shown in Table 1 . Real-time quantitative PCR was performed using a LightCycler 1.5 system (Roche Diagnostics, Indianapolis, IN, USA) using SYBR Green technology. Thermocycling conditions consisted of 22-30 cycles of denaturation for 10 s at 95°C followed by annealing and extension for 30 s at 60°C. The expression ratio of each gene relative to β-actin (relative gene expression) was calculated by subtracting the threshold cycle number (Ct) of the target gene from that of β-actin and raising 2 to the power of this difference.
Protein Extraction and Western Blot Analysis
Protein extracts were prepared from renal cortical tissue samples and cells using a standard method, and 40 μg of protein was electrophoresed on 10% SDS-PAGE minigels, and the membranes were incubated in blocking buffer overnight at 4°C with rabbit polyclonal anti-ATP-binding cassette transporter-1 antibodies ( Immunoreactive bands were detected using enhanced chemiluminescence reagents (Amersham, Buckinghamshire, UK).
Immunofluorescence Microscopy for DPPIV To confirm the presence of DPPIV in cultured podocytes, immunofluorescence staining was performed for CD26 (DPPIV). Podocytes were grown in a four-chambered glass slide and then fixed at RT for 10 min in 75% ethanol. The slides were incubated at 4°C overnight with rabbit polyclonal anti-CD26 antibodies (1:500; Abcam Plc) in a solution containing 0.2% Triton X-100. Nuclei were counterstained with DAPI. After rinsing in ice-cold PBS, slides were incubated with fluorescent-labeled (Alexa Fluor 488-conjugated) donkey anti-rabbit IgG secondary antibodies (1:200; Invitrogen, Carlsbad, CA, USA) for 1 h at 37°C.
In Vitro DPPIV Activity Experiments
The mouse podocyte cell line was obtained from Peter Mundel at the Albert Einstein College of Medicine, NY, USA. 
RESULTS

Kinetics of DPPIV Activity in Diabetic Mice
The levels of DPPIV activity over time in the plasma and various organs of nondiabetic vs diabetic mice are shown in Figure 1 . DPPIV activity was significantly higher in kidneys from diabetic mice than nondiabetic mice at the late stage of disease. However, DPPIV activity in the plasma and other organs was not significantly different between the two groups at this stage ( Figure 1a) . Interestingly, DA-1229 treatment markedly suppressed DPPIV activity in the plasma and all organs tested, including the kidney (Figures 1b and c) .
Effects of DA-1229 on Physical and Metabolic Parameters in db/db Mice
The biochemical and physical parameters tested are shown in Table 2 . The mean fasting blood glucose level, HbA1c level, body weight, urine volume, water and food intake, HOMA-IR, fat mass per body weight, and liver mass per body weight were all significantly higher in diabetic db/db mice than nondiabetic db/m mice. In contrast, the mean plasma level of adiponectin was significantly lower in diabetic db/db mice. Interestingly, DA-1229-treated db/db mice showed a significantly reduced water intake, fasting blood glucose level and plasma concentration of creatinine compared with vehicle-treated db/db mice. However, no significant differences were observed regarding body weight, food intake, urine volume, tissue weight, HbA1c, HOMA-IR, systolic blood pressures or plasma adiponectin level between the two groups. In addition, no significant differences were observed between the two groups regarding glucose tolerance or insulin resistance, as determined by the oral GTT and the ITT (data not shown). Although the levels of active GLP-1 were not significantly different between diabetic db/db mice and nondiabetic db/m mice, DA-1229 treatment significantly increased the level of active GLP-1 in both groups. In addition, plasma and urinary levels of inflammatory and oxidative stress markers such as MCP-1 and 8-isoprostane were significantly increased in diabetic db/db mice than those in nondiabetic db/m mice. DA-1229 treatment significantly improved plasma and urinary levels of inflammatory and oxidative stress markers (Table 2) . Interestingly, the DA-1229-treated group exhibited improved hepatic steatosis (Figure 2a ). In accordance with these changes, the plasma lipid profiles were significantly improved by DA-1229 treatment as compared with vehicle-treated db/db mice (Figure 2b ).
Effects of DA-1229 Treatment on Kidney Function and Structure
Throughout the duration of the experiment, urinary albumin excretion was significantly increased in db/db mice compared with db/m mice. This increased albuminuria was significantly attenuated by 8 weeks of DA-1229 treatment, and this decrease was maintained until 12 weeks of treatment ( Figure 2c ). In addition, histological sections of kidneys from DA-1229 treatment showed significantly attenuated glomerular tuft hypertrophy, mesangial expansion and macrophage infiltration (Figure 2d ). Consistent with these histological changes, immunohistochemical staining score and the mRNA expression levels revealed that the levels of profibrotic markers and macrophage infiltration were significantly ameliorated by DA-1229 treatment (Figures 3a and c) . However, the renal expression of the GLP-1 receptor was not significantly different between the two groups ( Figure 3d) . Interestingly, the expression of HMG-CoA reductase was markedly downregulated by DA-1229 treatment. On the other hand, the expression of adenosine triphosphate-binding cassette transporter A1 (ABCA1) was significantly upregulated by DA-1229 treatment (Figures 3c and d) .
Effects of DA-1229 on Urinary Excretion of Nephrin and Podocyte Injury
As shown in Figure 4a , DA-1229 treatment markedly decreased urinary excretion of nephrin. Moreover, nephrin expression was markedly downregulated in db/db mice compared with db/m mice, whereas DA-1229 treatment restored nephrin expression. Next, we investigated the expression of DPPIV in untreated (basal state) podocytes by IF and found that DPPIV exhibited a cytoplasmic distribution (Figure 4b ). To more clearly determine the cause of decreased urinary excretion of nephrin after DA-1229 treatment, we next investigated the effect of DA-1229 on podocyte loss by performing immunostaining with WT-1 and cell viability assay. As shown in Figure 4c , numbers of WT-1-positivestained cells in the glomeruli were significantly increased in DA-1229 treatment group compared with that in db/db mice group. In addition, we also observed that DA-1229 pretreatment significantly increased podocyte survival from high glucose-induced cytotoxic injury using MTT assay ( Figure 4d ). Next, we determined the effect of inhibiting DPPIV on nephrin synthesis in podocytes. Interestingly, stimulation with high glucose and angiotensin II markedly reduced the cellular level of nephrin, whereas treatment with DA-1229 most effectively restored nephrin production (Figure 4e ). 
Effects of DA-1229 on DPPIV Activity and Chemoattractant Protein Synthesis in Cultured Podocytes
We then evaluated whether high glucose and angiotensin II, two major mediators of DN, affect DPPIV activity in podocytes. Although no significant changes in DPPIV activity were observed after stimulation with high glucose, angiotensin II significantly increased DPPIV activity and stimulation with both high glucose and angiotensin II additively increased DPPIV activity in podocytes (Figure 5a ). Regarding the potencies of the various DPPIV inhibitors, DA-1229 and saxagliptin were the strongest inhibitors of all drugs tested, with DA-1229 reducing DPPIV activity by 50% when used at 10 nM ( Figure 5b ). As DA-1229 significantly decreased macrophage infiltration in the kidney, we next examined whether increased DPPIV activity induced upregulation of chemoattractant proteins such as MCP-1 and osteopontin. As shown in Figures 5c and e, high glucose and angiotensin II stimulation markedly increased MCP-1 gene expression and MCP-1 protein secretion in cultured podocyte. However, there was no significant change in osteopontin expression after stimulation with high glucose and angiotensin II. Furthermore, there was a significant positive correlation between DPPIV activity and supernatant MCP-1 levels in cultured podocytes (Figure 5f ).
Effects of DA-1229 on DPPIV Activity and Renal Injury in the Adriamycin Model
As DA-1229 significantly suppressed DPPIV activity and restored nephrin expression in cultured podocytes, we further examined the effects of DA-1229 on podocyte injury in adriamycin mice. Although plasma DPPIV activity was not significantly different in adriamycin mice compared with control mice, DPPIV activity in the kidney was significantly higher in the adriamycin mice (Figure 6a ). In addition, DA-1229 markedly decreased plasma and renal DPPIV activity when given both preventively and therapeutically to adriamycin mice (Figures 6b and c) . However, no significant differences in the levels of active GLP-1 were observed among the groups (Figure 6d ). In addition, urinary excretion of nephrin was markedly decreased in both the preventive and therapeutic groups of adriamycin mice (Figures 6e  and f) .
Effects of DA-1229 on Plasma and Urinary Inflammatory Molecules in Adriamycin Mice
As DPP4 inhibitor has shown to decrease proinflammatory cytokines and atherosclerotic process in both diabetic patients and animal models of diabetes independent of the effects on the glycemic controls, we also measured plasma and urinary levels of inflammatory and oxidative stress markers such as MCP-1 and 8-isoprostane in adriamycin model. Similar to the results in diabetic mice, DA-1229 treatment significantly decreased plasma and urinary levels of inflammatory and oxidative stress markers (Figure 7) .
Effects of DA-1229 on Renal Structural and Functional Changes in Adriamycin Mice
The renal pathology and immunostaining of F4/80, α-SMA and nephrin in DA-1229-treated and -untreated mice are shown in Figure 8a . PAS and α-SMA immunostaining revealed extensive glomerulosclerosis, interstitial fibrosis and tubular atrophy in untreated adriamycin mice. Interestingly, both the preventative and therapeutic groups of DA-1229-treated mice significantly decreased macrophage infiltration (Figures 8a and c) . In addition, numbers of WT-1-positivestained cells in the glomeruli were significantly increased in DA-1229 treatment group compared with that in adriamycin group (Figure 8b ). In accordance with the morphological alterations observed in the kidneys of adriamycin mice, the renal mRNA expression levels of proinflammatory and profibrotic cytokines were remarkably decreased with DA-1229 treatment (Figures 8d and e) . In accordance with these changes, DA-1229-treated mice abolished glomerulosclerosis and interstitial fibrosis in both the preventative and therapeutic groups (Figures 9a and b) . Proteinuria and albuminuria persistently increased after adriamycin administration, whereas both preventive and therapeutic DA-1229 treatment significantly prevented adriamycin-induced changes (Figures 9c and f) . In agreement with these observations, the renal expression of fibrotic proteins such as type I collagen and TGF-β 1 was markedly downregulated by both preventive and therapeutic treatment with DA-1229 ( Figure 9g ). As DA-1229 treatment markedly suppressed fibrotic process in the kidney, we next observed whether DA-1229 may contribute to the process of epithelialmesenchymal transition (EMT). However, we did not find any significant changes in the representative markers of EMT 
DISCUSSION
In this study, we demonstrated that a novel DPPIV inhibitor, DA-1229, exhibits renoprotective effects. These effects include significantly decreasing urinary albumin excretion, improving renal histological changes and lipid metabolism, and reducing macrophage infiltration in the kidney. Of particular note, we also found that DA-1229-mediated inhibition of DPPIV restored nephrin expression in podocytes and decreased podocyte injury in both db/db and adriamycin mice.
DA-1229 is currently in late-stage development for the treatment of type 2 diabetes. This molecule is a reversible and competitive inhibitor of DPPIV, with an inhibitory activity almost 6000-fold more selective for human DPP4 compared with human DPP8 or DPP9. 25 In streptozotocin-induced diabetic mice, DA-1229 has been shown to significantly reduce plasma DPPIV activity, enhance glucagon-like peptide-1 levels and improve insulin tolerance. 26 In high-fat diet-induced obese mice, long-term treatment with DA-1229 resulted in significantly improved glucose intolerance and insulin resistance. 27 In a phase I study performed in 72 healthy Korean male volunteers, each of whom received a single administration of DA-1229 ranging from 1.25 to 60 mg, DPPIV inhibition was found to be dose dependent, with groups receiving ≥ 10 mg exhibiting 480% DPPIV inhibition for 424 h. 28 In this study, we first observed DPPIV activity in the plasma and various target organs over time in diabetic mice. DPPIV activity was not significantly different in the plasma, hepatic tissue, cardiac tissue or adipose tissue of diabetic mice compared with control mice. However, DPPIV activity was significantly higher in the kidneys of diabetic mice compared with their nondiabetic controls. These results are consistent with recent reports that DPPIV expression is upregulated in human renal glomerular epithelial cells during inflammation 29 and in a rat model of type 2 diabetes mellitus, 30 which may suggest a role for DPPIV in the development of diabetic kidney disease. However, DPPIV activities in the plasma and all other target organs of diabetic mice were markedly reduced by DA-1229 treatment, with reductions of 70-80% in the plasma and kidneys. These results imply that the administered DA-1229 was successfully delivered to all organs and that it also systematically controlled DPPIV activity in diabetic mice. As expected, the plasma levels of active GLP-1 were significantly increased after DA-1229 treatment. However, these levels were not significantly different between diabetic db/db mice and nondiabetic db/m mice.
In this study, we observed that DA-1229 improved dyslipidemia without affecting the serum fasting blood glucose level or the amount of food intake. Although no differences were observed regarding the proportions of fat and liver weight, these findings are in agreement with a previous study showing that the liver expression of DPPIV correlates with the histopathologic grades of nonalcoholic steatohepatitis and hepatosteatosis. 31 The most important finding in this study is that DA-1229 mitigates the urinary excretion of albumin and mesangial expansion in renal tissue. Moreover, these effects are accompanied by the suppression of profibrotic and proinflammatory molecule synthesis. In support of the role of DPPIV inhibition in the inflammatory process, Nistala et al 32 recently reported that DPPIV inhibition prevents glomerular and tubular injury through reduction in renal oxidative stress and inflammation in high-fat diet-induced mice independent of blood pressure and insulin sensitivity. Interestingly, we also found that DA-1229 improved renal lipid metabolism in the diabetic kidney. DA-1229 treatment markedly suppressed the expression of genes involved in cholesterol synthesis, such as HMG-CoA reductase. On the other hand, ABCA1, which modulates cholesterol efflux, was significantly upregulated by DA-1229 treatment.
Furthermore, here we observed for the first time that podocyte DPPIV activity increases in response to stimulation with high glucose and angiotensin II. In addition, nephrin expression was markedly downregulated in the glomeruli of db/db mice compared with control db/m mice. Interestingly, DA-1229 treatment also increased nephrin expression in the glomeruli of diabetic mice. We also observed that numbers of WT-1-positive-stained cells in the glomeruli were significantly increased in DA-1229 treatment group compared with that in db/db mice group. In addition, we observed that DA-1229 pretreatment significantly increased podocyte survival from high glucose-induced cytotoxic injury using MTT assay. These findings are in agreement with a recent study showing that the DPPIV inhibition prevents podocyte loss associated with the suppression of oxidative damage. 33 Taken together, these results suggest that activated DPPIV may induce podocyte dysfunction, such as podocyte loss, which is accompanied by increased albuminuria. Another interesting finding was that various DPPIV inhibitors could differentially affect DPPIV activity and nephrin restoration. We found that DA-1229 and saxagliptin were the most potent inhibitors of DPPIV activity in podocytes, with DA-1229 showing the most potent effect on nephrin preservation in podocytes.
Recent studies have used animal models to investigate the possible beneficial effects of the DPPIV inhibitors sitagliptin, vildagliptin and linagliptin in diabetic nephropathy. 13, 14, 34 These studies found that DPPIV inhibition led to reduced albuminuria and histological damage; these effects were associated with anti-inflammatory and antioxidant properties. However, it is difficult to determine whether the renal effects of DPPIV inhibitors are independent of their glucose-lowering effects. Therefore, in this study, we investigated the effects of DPPIV inhibition in adriamycin nephropathy model to rule out any indirect effects from blood sugar changes. 35 Adriamycin-induced nephropathy is characterized by podocyte injury followed by glomerulosclerosis, tubulointerstitial inflammation and fibrosis. 36 Interestingly, DPPIV activity in the kidney was significantly increased in adriamycin mice compared with control mice, whereas no significant differences were observed between the two groups regarding the plasma level of active GLP-1. Surprisingly, we found that DA-1229 significantly reduced albuminuria and proteinuria; improved the expression of inflammatory and fibrosis-related molecules, and decreased macrophage infiltration. To further support the role of DPPIV activity in macrophage infiltration, we also demonstrated that high glucose and angiotensin II stimulation markedly increased MCP-1 gene expression and MCP-1 protein secretion as well as increased DPPIV activity, and there was a significant positive correlation between DPPIV activity and supernatant MCP-1 levels in cultured podocytes. Moreover, DA-1229 treatment significantly prevented the urinary loss of nephrin in adriamycin mice and in db/db mice. Nephrin is a crucial protein for maintaining the integrity of the slit diaphragm and nephrin excretion has been proposed to be an early indicator of podocyte injury, even before the onset of albuminuria. 36, 37 Collectively, these findings suggest that the renoprotective effects of DA-1229 are due to the suppression of DPPIV activity independent of the glucose-lowering effect and mediated by the prevention of podocyte injury. Our study differs from previous work, in that we directly determined DPPIV activity in the kidney, rather than simply measuring DPPIV expression. We showed that DPPIV activity was increased in the kidneys of diabetic mice and adriamycin nephropathy mice, and that DA-1229 treatment suppressed DPPIV activity, and that DA-1229 treatment resulted in improved renal function via podocyte protection.
In conclusion, our data suggest that DPPIV inhibitors may prevent renal disease progression in diabetic and nondiabetic kidney disease. These findings suggest that DA-1229 treatment is a promising novel strategy for targeting diabetic nephropathy, in addition to various other glomerular diseases affecting podocytes.
